Growth Metrics

Conmed (CNMD) Amortization of Deferred Charges (2019 - 2025)

Conmed (CNMD) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges rose 923.82% year-over-year to $14.8 million, compared with a TTM value of $57.1 million through Dec 2025, up 902.42%, and an annual FY2025 reading of $57.1 million, up 902.42% over the prior year.
  • Amortization of Deferred Charges was $14.8 million for Q4 2025 at Conmed, up from $14.2 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $51.1 million in Q4 2023 and bottomed at -$23.4 million in Q3 2024.
  • Average Amortization of Deferred Charges over 5 years is $6.4 million, with a median of $1.5 million recorded in 2022.
  • The sharpest move saw Amortization of Deferred Charges crashed 2830.24% in 2022, then soared 3294.16% in 2023.
  • Year by year, Amortization of Deferred Charges stood at $780000.0 in 2021, then soared by 93.08% to $1.5 million in 2022, then skyrocketed by 3294.16% to $51.1 million in 2023, then plummeted by 97.18% to $1.4 million in 2024, then surged by 923.82% to $14.8 million in 2025.
  • Business Quant data shows Amortization of Deferred Charges for CNMD at $14.8 million in Q4 2025, $14.2 million in Q3 2025, and $14.1 million in Q2 2025.